Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
TVRD
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
businesswire.com
8 hours ago
businesswire.com
8 hours ago
businesswire.com
16 hours ago
businesswire.com
16 hours ago
Forecast
-18%2026-Revenue
-641%2026-EPS
101%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
78.00(215.28%)
Number of analyst
1
Last analyst upgrade/downgrade
Raymond James
initialisePrevious: Not converted
2025-07-14
Now: Outperform
Cantor Fitzgerald
initialisePrevious: Not converted
2025-07-11
Now: Overweight
Piper Sandler
initialisePrevious: Not converted
2025-06-12
Now: Overweight
Oppenheimer
initialisePrevious: Not converted
2025-05-21
Now: Outperform
Quote Panel
Key Metrics
Earnings Growth
YoY
Current
Estimates
Q2.23
N/A
NA
vs NA
Q3.23
N/A
NA
vs NA
Q4.23
N/A
NA
vs NA
Q1.24
N/A
NA
vs NA
Q2.24
N/A
NA
vs NA
Q3.24
N/A
NA
vs NA
Q4.24
N/A
NA
vs NA
Q1.25
N/A
-3.22
vs NA
Q2.25
N/A
-0.68
vs NA
Q3.25
N/A
-0.85
vs NA
Sales Growth
YoY
Current
Estimates
Q2.23
NA
NA vs NA
Q3.23
NA
NA vs NA
Q4.23
NA
NA vs NA
Q1.24
NA
NA vs NA
Q2.24
NA
NA vs NA
Q3.24
-47%
2.6M vs 4.9M
Q4.24
NA
1.5M vs NA
Q1.25
+20%
2.6M vs 2.1M
Q2.25
+122%
2.2M vs 991K
Q3.25
-26%
1.9M vs 2.6M
Return on Equity
QoQ
Q4.22
NA
NA
vs NA
Q1.23
NA
NA
vs NA
Q2.23
NA
NA
vs NA
Q3.23
NA
NA
vs NA
Q4.23
+7%
0.07
vs -0.33
Q1.24
-103%
-1.03
vs 0.07
Q2.24
-173%
-1.73
vs -1.03
Q3.24
+16%
0.16
vs -1.73
Q4.24
+167%
1.67
vs 0.16
Q1.25
+61%
0.61
vs 1.67
Institutionnal Ownership
QoQ
Q1.23
NA
NA
vs NA
NA
Q2.23
NA
NA
vs NA
NA
Q3.23
NA
NA
vs NA
NA
Q4.23
NA
NA
vs NA
NA
Q1.24
NA
NA
vs NA
NA
Q2.24
NA
NA
vs NA
NA
Q3.24
NA
NA
vs NA
NA
Q4.24
NA
NA
vs NA
NA
Q1.25
NA
NA
vs NA
NA
Q2.25
30
30
vs NA
NA
Relative Strength
TVRD
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).
NASDAQ
Unprofitable
Unprofitable
0.74 ( 3.08%)
Relative Strenght
Volume Buzz
-82%
Earning Acce
Yes
Dist 52w H.
28%Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How TVRD compares to sector?
TVRD
-5x